


Replace Page 1, paragraph 3 with the following rewritten paragraph:

Q² Overproduction of cytokines such as IL-1 and TNF- α is implicated in a wide variety of inflammatory diseases, including rheumatoid arthritis (RA), psoriasis, multiple sclerosis, inflammatory bowel disease, endotoxin shock, osteoporosis, Alzheimer's disease, and congestive heart failure, among others. [See Henry *et al.*, *Drugs Fut.*, 24:1345-1354 (1999), and Salituro *et al.*, *Curr. Med. Chem.*, 6:807-823 (1999)]. There is convincing evidence in human patients that protein antagonists of cytokines, such as, for example, monoclonal antibody to TNF- α (Enbrel) [Rankin *et al.*, *Br. J. Rheumatol.*, 34:334-342 (1995)], soluble TNF- α receptor-Fc fusion protein (Etanercept) [Moreland *et al.*, *Ann. Intern. Med.*, 130:478-486 (1999)], and/or IL-1 receptor antagonist [Bresnihan *et al.*, *Arthritis Rheum.*, 41:2196-2204 (1998)], can provide effective treatment for chronic inflammatory diseases. As none of the current treatments for inflammatory diseases provides complete relief of symptoms, and as most current treatments are associated with various drawbacks such as side effects, improved methods for treating inflammatory diseases are desirable.


Delete the "paragraph" (Table row) at page 104, row 4 (begins with #).

Replace the compound of Example 59 with the following corrected formula:



Replace the compound of Example 81 with the following corrected formula:

Q4



Delete the table row at page 108, row 3 (begins with #);

Delete the table row at page 111, row 5 (begins with #);

Delete the table row at page 1115, row 4 (begins with #);

Delete the table row at page 120, row 3 (begins with #);

Replace the paragraphs beginning at page 124, row 5 (Table entry, example 363), and running through the end of page 128, with the following replacement paragraphs:

Q5

363	483.66		364	463.62	
365	435.57		366	480.61	
367	466.58		368	494.64	
369	452.56		370	437.54	










371	450.58		372	436.56	
373	485.63		374	505.63	
375	470.57		376	491.61	
377	440.59				

Table 2



#	R ²⁰	R ²¹	Compound	HPLC Ret. Time(min)	Mass Spec MH ⁺ (m/z)
378	CH ₃		O	2.89	466

as










379	H		P	3.01	458
380	H		Q	2.86	452
381	OCH ₃		R	2.99	488
382	OCH ₃		S	2.87	482
383	OCH ₃		T	2.80	460
384	CH ₃		U	2.80	444
385	H		V	2.70	430

Table 3



#	R ²²	R ²³	Compound	HPLC Ret. Time(min)	Mass Spec MH ⁺ (m/z)
386	H		C ₁	2.27	445
387	OCH ₃		D ₁	2.5	475
388	H		E ₁	1.99	417
389	OCH ₃		F ₁	2.1	447

Table 4



#	R ²⁴	R ²⁵	Compound	HPLC Ret. Time(min)	Mass Spec MH ⁺ (m/z)
390	CH ₃		K ₁	2.71	456
391	OCH ₃		L ₁	2.68	472
392	H		M ₁	2.57	436
393	CH ₃		N ₁	2.63	450
394	OCH ₃		O ₁	2.61	466
395	H		P ₁	2.51	414
396	CH ₃		Q ₁	2.59	428
397	OCH ₃		R ₁	2.57	444